Facebook
X
LinkedIn
ForwardThe Human Side of Breast Cancer: Using Novel Data and Patient Voices to Optimize Patient-centered Care in HER2-positive Breast Cancer Brain Metastases
Program Description
Breast cancer (BC) is the second most common cause of brain metastases (BM), with the highest risk—up to 50%—seen in patients with human epidermal growth factor receptor 2 (HER2)-positive disease. Individuals diagnosed with HER2-positive BCBM have historically faced poor long-term survival and limited effective treatment options. For years, these patients were excluded from randomized clinical trials, leaving oncology clinicians without clear, evidence-based guidance for optimal management. Today, emerging data from trials of modern systemic therapies and evolving treatment approaches are beginning to transform outcomes, although translating these advances into routine clinical strategy remains a challenge.
In this activity, BC experts provide guidance on their preferred screening and management approaches for HER2-positive BCBM. Videorecorded patient vignettes from individuals living with BCBM are interwoven into the discussions to provide context for how these clinical decisions affect patients and their support networks, underscoring the importance of shared decision-making (SDM) and comprehensive care planning.
Target Audience
This activity is intended for medical oncologists, neuro-oncologists, oncology fellows, advanced practice professionals (APPs), registered nurses, and pharmacists working in oncology care settings.
Learning Objectives
Upon completion of this activity, the learner should be able to:
- Describe the incidence and unique disease pathogenesis of HER2-positive BCBM to raise awareness among the medical community, improve screening practices, and ensure timely access to treatment
- Develop strategies to more effectively communicate and coordinate within the broader oncology care team (e.g., physician, APPs, social workers) to streamline care and improve quality of life (QoL) for patients with HER2-positive BCBM
- Appraise available and emerging research on the use of local and systemic treatment approaches for HER2-postitive BCBM to improve evidence-based decision making, treatment sequencing, clinical trial enrollment, and patient outcomes
- Incorporate patient experiences and perspectives surrounding available treatment approaches in HER2-positive BCBM during their implementation to improve patient centered care and SDM
Komal Jhaveri, MD, FACP
Javier Cortes, MD, PhD
Joyce A. O’Shaughnessy, MDJointly provided by Partners for Advancing Clinical Education and Efficient LLC in collaboration with SHARE Cancer Support.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
(Universal Activity Number - JA4008073-9999-25-295-H01-P)
Type of Activity: Knowledge-based
PA Continuing Medical EducationFaculty and Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Planners have no financial disclosures to report:
Sarah Hertrich
Nichole Lainhart
Brian Moss
Jessica Rucki
Dr. Jhaveri, faculty for this educational activity, has the following relevant financial relationships: Consultant/Advisory Board/Speakers Bureau: AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Daiichi-Sankyo; Eisai Inc.; Genentech, Inc.; and Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Available Credit
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance